Pfizer agrees to update Chantix warnings

Share this article:

Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...